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1. Introduction
Cancer stem cells are defined as cancer cells that show the two properties of stemness: un‐
limited self-renewal and, pluripotency or multipotency. These properties make cancer stem
cell tumorigenic i.e. the ability to induce and sustain cancer.
The definition of cancer stem cell has been a topic of debate and has changed with time.
Cancer stem cells were proposed in 1994 by John Dick and coworkers as the cells that initiat‐
ed leukemia [1]. It was thought that this leukemic cell was derived from the mutation of a
hematopoietic stem cell. Importantly, the term was used to distinguish a small subpopula‐
tion of leukemic cells that could initiate and maintain cancer from the rest of the leukemic
cells that could not. Subsequently, it was also observed in other types of cancer that only a
very small subpopulation of cancer cells had the ability to initiate cancer when transplanted
into a new host [2–12]. This subpopulation of cancer cells was considered as cancer stem
cells. The rest of the cancer cells, which ranged from progenitor to fully differentiated cancer
cells, that formed the bulk of the cancer had limited proliferative capacity and hence could
not initiate cancer when transplanted. Since cancer comprise a heterogeneous collection of
cells, a unique set of cell surface markers that were expressed on cancer stem cells were used
to define them.
The definition underwent revision when new experimental methods showed that turmori‐
genicity had been underassigned to a small group of cells due to limitations of the detection
technique used. When different experimental approaches were undertaken, tumorigenicity
was found to be widespread amongst phenotypically diverse cancer cells, resulting in a
paradigm shift in the definition of cancer stem cells. Hence in 2006, the American Associa‐
tion of Cancer Research (AACR) defined a cancer stem cell as any cancer cell that possessed
stem cell-like properties of unlimited self-renewal and multi/pluripotency. AACR specifical‐
ly highlighted that the definition of a cancer stem cell does not imply that such cells are de‐
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rived from the stem cells of the corresponding tissue. Also, a cancer stem cell does not have
to be that initial cell in the body that caused cancer. For example, a differentiated cell that
reacquires immortality through genetic mutations is considered a cancer stem cell. Thus any
cancer cell that possesses or acquires stemness which results in unlimited tumorigenic po‐
tential is considered a cancer stem cell.
More recently, interesting data has emerged demonstrating that partially differentiated can‐
cer cells, when exposed to a specific set of microenvironmental factors, can reacquire stem‐
ness [13]. Induction of stemness through this mechanism is reversible and could also result
in epigenetic modifications, which then becomes heritable. This finding would again modify
our understanding of the nature of cancer stem cell, suggesting that the cancer stem cell can
be a dynamic and reversible entity.
In this section, experimental data shaping the identification and definition of cancer stem
cells are presented in three parts. It begins with a description of early studies demonstrating
that cancer stem cells were found to be a small and distinct subpopulation of cancer. This is
followed by evidence suggesting that cancer stem cells can also be a highly common and
heterogeneous population of cancer cells. Finally, evidence that cancer stem cell is a dynam‐
ic and reversible entity in cancer is discussed.
1.1. Cancer stem cells: A distinct subpopulation of cancer cells
The concept of cancer stem cell is not new. The first experimental evidence for the existence
of cancer stem cell was in 1937 when Furth and Kahn injected a single leukemic cell from a
mouse into an inbred mouse and transmitted leukemia [14]. At that time, it was unclear if
every cancer cell or only a subpopulation of cancer cells possessed this ability to transmit. In
1994, a landmark experiment showed that only a subpopulation of cancer cells could trans‐
mit cancer [1]. John Dick and his group isolated cancer cells from patients with acute mye‐
loid leukemia (AML) and separated these cells based on their expression of CD34 and CD38.
In this study, transplanting half a million of CD34+CD38- cells into severe combined immu‐
nodeficiency (SCID) mice induced AML in mice within thirty days, while the same number
of CD34+CD38+ cells did not induce any AML in mice. The subpopulation of cancer cells
that could transmit cancer was termed SCID-leukemia initiating cells and was thought to be
amongst CD34+CD38- cells.
To determine the amount of the SCID-leukemia initiating cells within the CD34+CD38- cell
population, a quantitative transplantation approach was used [15]. The cancer cells were se‐
rially diluted and transplanted into NOD/SCID (non-obese diabetic/severe combined immu‐
nodeficiency) mice. The minimum dose required to cause leukemia was then determined.
Based on this experiment, it was found that there was about one cancer stem cell per 5,000
CD34+CD38- cells. This would mean that within a population of a million cancer cells, there
was about one cancer stem cell. The ability of cancer stem cell to self-renew was provided by
experiments that used the same transplantation approach described above, i.e. using human
leukemic cells and NOD/SCID mice [15]. In one of these experiments, the number of human
cancer stem cells in mice was initially found to be about three in 16 million leukemia cells.
However, after six weeks, human cancer stem cells had increased to about 100 cancer stem
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cells within a population of 20 million leukemia cells in the bone marrow of these mice. This
indicated that SCID-leukemia initiating cells in the mice had multiplied from three to a 100
and therefore behaved like stem cells, possessing unlimited self-renewal ability.
Evidence that cancer stem cells could differentiate into the rest of the cancer cell population
was provided by characterizing the CD34+CD38- cells after transplantation into NOD/SCID
mice [15]. Flow cytometry analysis of human cells isolated from the bone marrow of mice
showed that transplanting CD34+CD38- cells resulted in an increase in cancer cell popula‐
tion, of which 98% were positive for both CD34 and CD38. This differentiative capacity, to‐
gether with self-renewal ability, led to the conclusions that cancer stem cells existed and
formed a distinct subpopulation of cancer cells.
Following the identification of cancer stem cells in leukemia, a series of in vivo studies docu‐
menting the presence of cancer stem cells in other cancers came to light. These studies, sum‐
marized in Table 1, characterized human cancer-initiating cells by their surface markers and
were based mostly on the NOD/SCID mouse xenotransplantation assay. The table highlights
information regarding the frequency of expression of cancer-stem cell-associated markers in
the cancer cells, and the estimated frequency of the cancer stem cells residing in the cell pop‐
ulation that bears the cancer stem cell-associated markers. Based on these studies, it was es‐
timated that cancer stem cell existed in, at most, one in ten thousand cancer cells.
Importantly, it was shown that this small population of cancer stem cells had a distinct CD-
phenotype, which when fully defined would serve as the address for accurate delivery of
cytotoxic drugs.
In addition to the use of NOD/SCID mice, in vitro techniques that were previously used for
the isolation of normal stem cells were also used to isolate cancer stem cells. These techni‐
ques included the formation of non-adherent spheroids in tissue culture method [10] and
the exclusion of the fluorescent Hoechst dye method [16]. Both methods led to the identifica‐
tion of a subpopulation of cells that, when transplanted into mice, resulted in tumorigenici‐
ty. Hence both in vivo and in vitro studies suggested that tumorigenic cancer cells were
stem-like in phenotype.
1.2. Cancer stem cells are not ALWAYS a distinct subpopulation of cancer cells
After a decade of using human cancer cells with NOD/SCID mouse as a model for can‐
cer  stem  cell  detection,  there  were  concerns  of  incompatibility  issues  between  the  two
species with regards to the cytokines and receptors involved in cancer stem cell research.
Cytokines  and  receptors  from  different  species  could  prevent  critical  interactions  that
were  required  for  cancer  cells  to  survive.  Furthermore,  the  NOD/SCID mouse  immune
system, even though rendered compromised, could still mount some level of response to
reject  the  human cells,  thereby  potentially  resulting  in  erroneously  lower  count  estima‐
tion of cancer stem cell population.
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Markers for enrichment of
cancer stem cells
Cancer type Cancer stem cell detection assay Ref.
CD34+ CD38- Leukemia
(0.02-2% of mononuclear
cells)a
2 of 2 NOD/SCID mice
(5,000 cells)b
[1,15]
CD44+
Lin-
Head and Neck cancer
(0.1-42%)
5 of 7 NOD/SCID mice
(5,000 cells)
[20]
CD44+ ESA+ CD24- or low Lin- Breast cancer
(2%)
4 of 4 NOD/SCID mice
(200 cells)
[2,4]
CD44+ CD24- ALDH1+ Lin- Breast cancer
(0.1-1.2%)
NOD/SCID mice
(20 cells)
[21]
CD44+ ESA+ CD24+ Pancreatic cancer
(0.2-0.8%)
6 of 12 NOD/SCID mice
(100 cells)
[12]
CD44+ ESAhigh CD166+ Colon cancer
(1.2-16%)
1 of 2 NOD/SCID mice
(150 cells)
[3]
CD44+ CD117+ Ovarian cancer
(0.2%)
9 of 10 nude mice
(100 cells)
[11]
CD133+ Brain cancer
(6-29%)
4 of 4 NOD/SCID mice
(100 cells)
[10]
Colon cancer
(1.8-24.5%)
5 of 6 NOD/SCID mice
(500 cells)
15 of 30 NOD/SCID mice
(3,000 cells)
[6]
[8]
Lung cancer
(0.32-22%)
4 of 4 SCID mice
(10,000 cells)
[5]
Pancreatic cancer
(1.1-3.2%)
Nude mice
(500 cells)
[22]
ABCB5+ Melanoma
(1.6-20.4%)
11 of 11 NOD/SCID mice
(1,000,000 cells)
[9]
Table 1. Experiments using markers for the enrichment of human cancer stem cells and xenotransplation assay for the
detection and quantification of human caner stem cells. An estimation of the population of cancer stem cell in a
tumor is given based. Epithelial-specific antigen (ESA) and ATP-binding cassette B5 (ABCB5) are surface markers.
Aldehyde dehydrogenase 1 (ALDH1) is an enzyme inside the cell. Lin refers to a collection of lineage markers CD2,
CD3, CD10, CD16, CD18, CD31, CD64 and CD140b. Mice were condition by irradiation prior to receiving the
transplantation. aPercentages of tumor cells expressing the selected markers. bMinimum number of surface-marker
expressing cells required to induce cancer in at least 50% of the mice.
To address these concerns, alternative experimental models were used. The first model used
mouse cancer cells instead of human cancer cells to circumvent the issue of cross species
barrier. One of these experiments involved transplanting mouse leukemic cells from trans‐
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genic mice bearing the oncogene Myc with the immunoglobulin heavy chain enhancer. Just
ten mouse leukemic cells were sufficient to induce cancer. Indeed, this experiment recapitu‐
lates the very first experiment in 1937 in which a single cancer cell from a chemically-in‐
duced cancer mouse was able to cause cancer in an inbred mouse [14,17]. This suggested
that cancer stem cells were not necessarily a small population of cancer cells but rather
could be more common than previously thought.
In the second model, human cancer cells continued to be used. However, they were trans‐
planted into mice that were rendered even more severely immunocompromised than NOD/
SCID mice [18]. In one such study where NOD/SCID ILR2γnull mice were used, 27% (and
hence more than a quarter) of single cell transplantation of human melanoma cells into the
mice resulted in cancer [18,19]. Importantly, this experiment showed that these cancer stem
cells were not associated with any of the surface markers that were previously characterized
(See Table 1). A total of 85 cell surface markers from these cancer stem cells were studied. Of
these, 22 cell surface markers showed heterogeneous expression within the cancer cell popu‐
lation of which none had an association with the capacity for tumor initiation. For example,
both CD133+ and CD133- cells were able to induce cancer [19]. In addition, the cancers that
resulted from both CD133+ and CD133- cancer cells created a population of cancer cells that
was heterogeneous in their expression of CD133. These findings implied that cancer stem
cells were both common and heterogeneous. Hence, these 2 models showed that cancer stem
cells were not a small, distinct subpopulation of cancer cells but rather a common and heter‐
ogeneous population of cancer cells in cancers such as melanoma.
Amidst the new findings that challenged the concept of cancer stem cells as a small, distinct
subpopulation of cancer cells, there were experiments which still showed that the cancer
stem cell subpopulation was indeed low, and not common and heterogeneous, even when
syngenic mice were used [23]. Interestingly, human experiments (which could not have been
conducted currently due to ethical reasons) provided evidence that when human cancer
cells were transplanted back into the human subject from whom the cancer cells originated,
the likelihood of cancer-initiation in the autologous human host is rare [24–26].
Taking all the evidence together, cancer stem cells are indeed a small and distinct subpopu‐
lation of cancer cells in some cancers, whereas in other cancers, cancer stem cells are com‐
mon and heterogeneous. An alternative explanation that could account for these varied
observations about cancer stem cells is that a cancer stem cell is not a static entity but rather
a state that cancer cells can transform into.
1.3. Cancer stem cells are dynamic
Even more recently, it has been shown that a partially differentiated cancer cell, under the
“right“ microenvironmental influence, can reacquire stemness [13]. This finding is crucial in
furthering our understanding of the cancer stem cell as a dynamic and reversible entity,
rather than a static one.
In a study on colorectal cancer, differentiated colorectal cancer cells were able to dedifferen‐
tiate back into cancer cells with cancer stem cell phenotype after being exposed to hepato‐
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cyte growth factor (HGF) [27]. Upon exposure, these cells showed increased colony-forming
ability (clonogenicity) and increased tumorigenicity. Biochemically, the cells exhibited an in‐
crease in the Wnt signaling pathway leading to the expression of β-catenin dependent genes.
This finding is important as HGF is present within the natural microenvironment of colorec‐
tal cancer as it is normally produced by myofibroblasts which are prominent in the colorec‐
tal stroma. Hence, given the right microenvironment, non-tumorigenic cancer cells can
become cancer stem cells.
Similarly, in a separate study using PDGF-induced glioma in mice, exposure to nitric oxide
caused differentiated glioma cancer cells to transform into glioma cancer stem cells [25].
Again, nitric oxide is normally present in the natural microenvironment of gliomas as nitric
oxide is produced by blood vessels. Hence glioma cancer cells in close proximity to brain
blood vessels were able to re-acquire stem-like properties. These two recent studies present‐
ed reiterate the concept that cancer stem cells are dynamic - cancer cells are able to trans‐
form back into cancer stem cells given the right micorenvironmental conditions.
1.4. Conclusions
Cancer stem cells are cancer cells that have self-renewable and multi or pluripotent abilities.
Our current understanding is that cancer stem cells can be a distinct subpopulation of cancer
cells in certain cancers while in other cancers, they can be relatively common and heteroge‐
neous. They are also dynamic in nature.
Understanding the defining characteristics of cancer stem cells is important as these have
important therapeutic implications. In cancers in which the cancer stem cells form a distinct
subpopulation, eliminating this subpopulatuion of cancer stem cells can potentially lead to a
cure. In contrast, targeting one specific group of cancer stem cells in cancers in which the
cancer stem cells are common and heterogeneous would be futile. In addition, learning
more about the microenvironmental factors that promote the cancer stem cell state provides
another interesting approach in finding a cure for cancer.
2. Cancer stem cell: The survivor
Chemotherapeutic agents against cancer are able to reduce tumor mass significantly but of‐
ten a cure may not be achievable. In such cases, a cure is not possible due to a subpopulation
of cells that are resistant to cancer drugs. The cancer stem cells amongst this resistant popu‐
lation then self-renew, proliferate and metastasize to cause relapse after treatment. In addi‐
tion to understanding the defining characteristics of cancer stem cells for therapeutic
purposes, a working knowledge of the molecular mechanisms of drug-resistance in cancer
stem cells will empower researchers to better design new therapeutic agents that can over‐
come drug resistance. We will also explore the mechanism for metastasis in cancer stem
cells, which serves as another potential therapeutic target.
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2.1. Drug resistance
Normal stem cells have traits that confer high survival capacity under harsh environments.
These include (1) cell quiescent, (2) active DNA-repair system, (3) expression of transporters
that keeps toxic substances out, (4) high metabolism in detoxification, and (5) resistance to
apoptosis. These mechanisms are thought to be employed by cancer stem cells, in addition
to genetic mutations, to evade anti-cancer drugs.
2.1.1. Cell quiescence
Chemotherapeutic cancer drugs such as vincristine, vinblastine, paclitaxel and docitaxel
works by arresting cancer cells in mitosis, thus leading to apoptosis [28]. One hypothesis to
explain resistance of cancer stem cells to these drugs is that cancer stem cells are in a quies‐
cent state. Indeed, quiescent cancer stem cells have been shown to exist in some cancers [29].
Moreover, drug resistance in slow-cycling cancer stem cell population has also been report‐
ed [30,31]. In addition to cell quiescence, cancer stem cells are likely to have other mecha‐
nisms for drug resistance as discussed below.
2.1.2. DNA-repair
Ionizing radiation and anti-cancer drugs that disrupt the genome kill cancer cells by target‐
ing their DNA. Cancer stem cells have efficient DNA-repair systems that confer resistance to
these anti-cancer agents. A study on glioblastoma demonstrated that cancer stem cells, iden‐
tified by their expression of CD133, showed preferential activation of the DNA damage
check point response resulting in an increase in their DNA repair capacity [32]. The study
also shows that both in vitro as well as mouse brain samples of cancer cells have increased
the proportion of CD133-positive cells to CD133-negative cells following radiotherapy. This
suggested that the subpopulation of CD133-positive, i.e. cancer stem cells, had developed
resistance to radiotherapy and were the cause of cancer relapse in the mouse.
2.1.3. Drug transporters
A third mechanism of drug resistance is the expression of transporters of the ATP-binding
cassette (ABC) family. ABC transporters are efflux pumps that can actively expel a wide
range of chemotherapeutic drugs from the cell. ABC transporters are expressed in both nor‐
mal stem cells and cancer stem cells. Three members of this family of ABC transporters,
ABCB1, ABCC1 and ABCG2 have been identified as the culprits of multidrug resistance in
many cancers.
A study on neuroblastoma patients illustrates how cancer stem cells use the efflux transport‐
er, ABCG2 to protect themselves from anti-cancer drugs. In this study, cells expressing
ABCG2 were identified by the fluorescent Hoechst dye 33342, in flow cytometry, as a “side
population“ (SP) of cells that did not take up this dye. A previous study had shown that
cancer stem cells reside in the SP fraction of neuroblastoma [10]. SP cells from neuroblasto‐
ma patients showed increased efflux of mitoxantrone when compared to non-SP cells. Also,
treatment of neuroblastoma cell lines with mitoxantrone led to an increase in the proportion
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of SP cells to non-SP cells, suggesting that ABCG2 conferred a survival advantage to cancer
stem cells [33]. Similarly, in acute myeloid leukemia, SP cells derived from mononuclear
cells in bone marrow of patients showed an increase efflux of daunorubicin and mitoxan‐
trone when compared to non-SP cells [34]. Taken together, these findings suggest that can‐
cer stem cell uses efflux transporters to guard against anti-cancer drugs.
2.1.4. High detoxification activity
Aldehyde dehydrogenase I (ALDH1) is a detoxifying enzyme that oxidizes intracellular ald‐
hydes and is a marker of normal stem cell. Cancer stem cells from acute myeloid leukemia
and breast carcinoma are known to have high levels of ALDH1. [21]. In breast cancer pa‐
tients undergoing chemotherapy with paclitaxel and epirubicin, it was found that the pro‐
portion of ALDH1-positive cancer cells increased significantly post treatment, resulting in
treatment failure[35]. A high ALDH1 level is thus associated with poor clinical outcomes.
This finding indicates that new therapeutic agents must be able to overcome the detoxifica‐
tion prowess of cancer stem cells in order to be effective.
2.1.5. Blockage of apoptosis
Blockage of apoptosis is a major mechanism for drug resistance as it offers protection
against any therapy that results in cell destruction. This ability to prevent apoptosis from oc‐
curring in cancer stem cell is mediated by both inherent cellular factors and extrinsic micro‐
environmental factors.
Inherent cellular factors are important in blocking the apoptotic process. In a study on can‐
cer stem cells (isolated via CD133) from glioblastoma, exposure of cancer cells to conven‐
tional chemotherapeutics such as temozolomide, carboplatin, paclitaxel and etoposide,
showed that CD133-positive cells had higher viability compared to CD133-negative cells
[36]. In contrast to CD133-negative cells, CD133-positive cells had higher mRNA levels of
the anti-apoptotic proteins, such as B-cell lymphoma (Bcl) -2 and -XL proteins, inhibitors of
apoptosis proteins (IAPs), FLICE-like inhibitory protein (FLIP) and Sirtuin 1 (SIRT1). In ad‐
dition, CD133-positive cells had lower mRNA level of the pro-apoptotic protein, including
Bcl-2 associated X protein (BAX). In a separate study on colon cancer, autocrine production
of interleukin-4 (IL4) by CD133-positive colon cancer cells was found to prevent apoptosis
of cancer stem cells from occurring when conventional chemotherapeutics and a recombi‐
nant protein called TNF-related apoptosis-inducing ligand (TRAIL) were used [37]. These
findings show that cancer stem cells have an armament of proteins to protect themselves
from undergoing apoptosis.
In some cancers, resistance to apoptosis is highly dependent on extrinsic microenvironmen‐
tal factors. For example, culturing ovarian cancer cells under stem cell culture conditions led
to formation of spheroid cultures of cells that were self-renewing and resistant to cisplatin
and paclitaxel [38]. However, this resistance was lost once the cells were cultured under a
different set of conditions. One extrinsic factor that has been recognized as the main cause
for resistance to cancer therapeutics is hypoxia. The normal stem cell niche has been associ‐
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ated with a hypoxic microenvironment. Expression of hypoxia-inducible factors (HIF) are
important as these factors regulate stem cell self-renewal and pluripotency [39]. Although
not well studied in cancer stem cells per se, the role of HIF in regulating apoptosis has been
shown in cancer cell cultures. HIF directly regulates the transcription of anti-apoptotic genes
such as myeloid cell leukemia 1 (MCL-1) and B-cell lymphoma extra-large (BCL-XL) [40,41].
Hypoxia also results in a lower level of reactive oxygen species (ROS) in the cell. A lower
level of ROS leads to a decrease in activation of caspase-8, a decrease in expression of pro-
apoptotic receptor TRAIL-R2 and an increase expression of pro-survival proteins like cFLIP
and BCL-2 [42,43].
Besides the extrinsic chemical factors described above, another type of extrinsic factor that
blocks apoptosis is the stimulating ligands produced by neighboring cells. The hematopoiet‐
ic niche has been found to confer resistance to leukemic cells via adhesion molecules such as
integrins and soluble molecules of the Wnt pathway [44]. Wnt, Notch and Hedgehog are de‐
velopmental regulatory molecules that are increasingly shown to be involved in cancer stem
cell self-renewal, growth and differentiation [27,45–50]. Therapeutics targeting factors of
these pathways are currently undergoing clinical trials and have shown promising results in
eliminating cancer stem cells that are resistant to existing therapies.
2.2. Metastasis
Tumorigenicity is an essential characteristic that metastatic cancer cells must possess in or‐
der to initiate tumor formation after metastasizing to a distant site. Hence, it can be assumed
that cancer stem cells are responsible for metastasis as they have tumorigenic properties by
definition. Recent findings suggest that not all cancer stem cells have the capacity to meta‐
stasize. Rather, this capacity is confined to a subset of cancer stem cells. Cancer stem cells
(identified by their CD 133 marker) isolated from pancreatic cancer patients were found to
contain a subset of cells that expressed CXCR4, the receptor for stromal-cell derived factor 1
(SDF-1). These cancer stem cells that expressed CXCR4 were able to induce tumors in mice,
spread via the blood circulation and cause liver metastasis. On the other hand, cancer stem
cells that were CXCR4-negative were only able to induce tumors in mice, failing to spread
and cause metastasis [22]. In light of this finding, therapies targeting this subset of cancer
stem cells could prevent metastasis.
2.3. Conclusions
The multitude of research in cancer stem cell has deepened our understanding in this field.
We present a schema (figure 1) that summarizes the literature in cancer stem cell research
from a therapeutic perspective. This schema illustrates that targeting cancer cells with tu‐
morigenic abilities, i.e. cancer stem cells, is not enough. It is the problematic subset of resist‐
ant cancer stem cells (outlined black in figure 1) that accounts for failure of current cancer
therapies. Overcoming resistance in cancer stem cells is crucial and we have described sev‐
eral mechanisms that cancer stem cells use to stem our efforts for a cure. One innovative ap‐
proach to eliminate resistant cancer stem cells is differentiation therapy, where cancer stem
cells are made to differentiate, thereby losing their resistant capabilities [51].
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Figure 1. Properties of cancer cells. The subset of tumorigenic cells that are also drug-resistant should be targeted to
ensure elimination of cancer.
3. Molecular targets for cancer therapy
3.1. Current clinical drug trials targeting cancer stem cells
Translating research from bench to bedside is perhaps the most challenging and rewarding
part of science. The development of drugs against cancer stem cell is an exciting field with
many different, innovative approaches. In this section, a review of the drugs that have al‐
ready reached clinical trials is presented (Table 2).
One approach is the targeting of the cancer stem cell machinery. An example of this ap‐
proach is the telomerase inhibitors. Telomeric inhibitors block replication and a clinical can‐
didate Imetelstat have shown efficacy in cancer stem cells [52]. As a bonus, telomerase
inhibitors are expected to also target the bulk of the tumor. Importantly, unlike normal stem
cells, cancer stem cells express higher levels of telomerase [53]. Hence this could potentially
be a drug that targets cancer stem cells without hurting normal stem cells.
In a second approach the targeting of the cancer stem cell phenotype, the immunogenic-re‐
sponse that ironically had been a problem to researchers in the detection of cancer stem cells
using the mouse model, has become a solution against cancer stem cells. In a study in which
cancer stem cells were injected into immunocompetent syngenic mice, cancer stem cells in‐
duced antitumor response more effectively than unselected cancer cells [54]. This finding is
important and has led to the development of various clinical candidates by three different
pharmaceutical companies. These candidates, all of which are currently in clinical trials,
were developed based on cancer stem cell-associated proteins. These proteins serve as anti‐
gens to evoke an immune response against cancer stem cells. In essence, these proteins act as
vaccines against cancer stem cells. Immunocellular Therapeutics has developed a dendritic-
based vaccine comprising dendritic cells that were obtained from patients and primed in vi‐
tro by two CD133-peptides. This vaccine has just recently been approved for phase I clinical
trials. Using the same approach, other clinical candidates were developed by two pharma‐
ceutical companies. Instead of obtaining dendritic cells from patients, peptides of cancer
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stem cell antigens were injected directly into patients to prime the immune system against
cancer stem cells. The peptides used in these vaccinations are found in both cancer stem
cells and non-stem cancer cells. One of these antigens is Wilms’ Tumor 1 (WT1). WT1 is a
transcription factor that is expressed in leukemia. Although a direct association between
WT1 and the leukemic stem cell has never been shown, WT1 however, has been associated
with the CD34+CD38- cell population which is thought to harbor the hematopoietic stem
cell [55] and also the leukemia stem cell [15].
Drug target Drug name Cancer Stage Company
Undisclosed Cancer stem cell inhibitor
BBI608
Colorectal cancer Entering Phase III Boston Biomedicals, Inc
Telomerase (inhibitor) Imetelstat Broad range Phase II Geron Corporation
CD-133 Dendritic cell-based vaccine
ICT-121
Glioblastoma Entering phase I ImmunoCellular
Therapeutics Ltd.
Focal adhesion kinase
(inhibitor)
VS6063 Advance solid
tumors
Phase I
completed
Verastem and Pfeizer
Wilms Tumor 1 Peptides from Wilms Tumor 1
(FPI-01)
Leukemia and
mesothelioma
Phase II Formula
Pharmaceuticals
EphA3 Human monoclonal antibody
(KB004) binds EphA3
Leukemia Phase I KaloBios
Pharmaceuticals, Inc.
Notch pathway Anti-DLL4 (demcizumab) Solid Tumors Phase I OncoMed
Anti-Notch2/3 (OPM-59R5) Solid tumors Phase I
Wnt pathway Anti-Fzd7 (OMP-18R5, binds 5
Frizzled receptors)
Solid Tumors Phase I
Truncated Frizzled 8-Fc fusion
protein
(OMP-54F28)
Advance solid tumor
cancers
Phase I
Undisclosed cancer
stem cell antigen
Peptides vaccine (SL401 and
SL701)
Advance leukemia
and advance brain
cancer
Phase I/II
completed
Stemline Therapeutics
Table 2. Current clinical drug trials in cancer stem cell therapy
A third approach is the targeting of the cancer stem cell and its microenvironment. Anti-
EphA3 antibody is a clinical candidate against cancer stem cell that has been developed by
KaloBios. This antibody treatment is now in phase I trial. EphA3 expression is found in preB
leukemia cell line and in a subset of samples from leukemia patients [56]. There is no direct
evidence that links EphA3 expression to the leukemic stem cells, however, in an in-house
study by KaloBios, incubating anti-EphA3 with cancer cells leads to the cancer cells losing
their ability to form colonies in vitro, suggesting that the antibody was active against cancer
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stem cells. In addition, the antibody was also found to bind to EphA3 that was expressed on
cancer vasculature cells as well as cancer stromal cells. The binding was reported to cause
cell-cell repulsion, resulting in the destruction of new vessels and failure to establish a can‐
cer stromal environment [57]. This strategy, which targets a protein that is found in cancer
stem cell, cancer stromal cells and cancer vasculature cells, would be “killing-three-birds-
with-one-stone“. Other clinical candidates that are based on a similar approach have also
been developed via targeting the Wnt pathway and the Notch Pathway instead [47–50].
3.2. Potential new targets – Insights from Pluripotent Stem cells
The discovery that transcription factors, namely, Oct4, Sox2, Klf4 and c-Myc, can induce
pluripotency in a differentiated adult cell [58], accelerated the understanding of the molecu‐
lar machinery driving pluripotent stem cells. Systems biology approaches based on these
transcription factors generated genome-wide regulatory networks that are thought to be the
supporting framework for an embryonic stem cell state. These data serves as a rich resource
in furthering our understanding of the cancer stem cell.
In a recent study of regulatory networks in embryonic stem cell, analysis of the protein-pro‐
tein interactions of key transcription factors and the downstream targeted genes revealed
that the embryonic stem cell regulatory network can be divided into three independent
modules (Figure 2). The three modules are the core module, the c-Myc module and the Poly‐
comb Repressive Complex (PRC) module. The core module comprises genes that are regu‐
lated by the embryonic stem cell-specific transcription factor Oct4 and Oct4-associated
proteins while the PRC module comprises genes that are repressed by the PRC. The Myc-
module comprises genes that are regulated by c-Myc and its associated proteins. Proper
functioning of all three modules are essential for having a normal pluripotent stem cell [59].
Using the 3-module model to study the genes expressed in bladder cancer and breast cancer
samples, it was found that the Myc module was more active in cancers while that of the core
module was more repressed, when compared to normal urothelium obtained from a distant
site of the cancer [61,62]. This suggested that in cancer cells, the Myc module is re-activated
but is not balanced by a core module. It should be noted that this comparison was done with
the heterogeneous cancer cell population and not the cancer stem cell population. Repeating
the same characterization analysis on cancer stem cell samples will likely highlight the key
differences between the regulatory network of cancer stem cells and that of normal pluripo‐
tent stem cells. These differences could become potential targets for anti-cancer therapy.
Factors that are crucial for the maintenance of pluripotent stem cell have been found to be
involved in cancer. Hypoxia-inducible factors (HIFs) have been found to be important in
pluripotent stem cell [39,63]. Studies now show that HIFs could be the key factor in switch‐
ing on the pluripotency machinery in cancer cells to form cancer stem cells [64]. In an experi‐
ment where glioma cells and cervical cells were exposed to HIFs, activation of the
embryonic stem cell marker, Oct4, was observed [65]. Subjecting glioma cells to hypoxia re‐
sulted in an increase in the level of CD133 mRNA [65]. In samples from glioma patients,
subjecting the CD133-positive fraction to hypoxia resulted in increased mRNA levels of
OCT4, NANOG and cMYC. Interestingly, when CD133-positive and negative fractions were
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cultured under hypoxic conditions, embryonic stem cell-association gene expression and
formation of neuroshpere were seen in both fractions [65]. Thus, low levels of oxygen pro‐
motes the transformation of cancer cells into cancer stem cells by activating the pluripotency
machinery in cancer cells with expression and repression of modules that are similar in pro‐
file to embryonic cells. This should be taken into consideration when targeting cancer cells.
Studies on HIF have shown that both HIF-1α and HIF-2α h are associated with cancer.
HIF-1α has been shown to play a role in angiogenesis [66] and anti-angiogenesis therapies
targeting HIF-1α have been undertaken [67,68]. In contrast, recent findings suggest that
HIF-2α is involved in the triggering of stemness in cancer which in turn promotes cancer
growth and aggressiveness [69]. Hence a potential pathway to target cancer stem cell will be
the HIF-2α-mediated pathway.
Figure 2. The three sets of genes that are activated or repressed by distinct sets of transcriptional regulators. Induce
pluripotent stem (iPS) cells show similar gene expression profile as embryonic stem (ES) cells. Mouse embryonic fibro‐
blast (MEF) represents a set of differentiated cells and shows a profile that is opposite to that of ES cells. Analysis of
the profile in cancer highlights a pluripotency machinery in which the core module has been suppressed and the Myc
module overactivated. Figure is a reprint of the graphical abstract provided by Kim et al [60] (Reprinted with permis‐
sion from Cell Press)
Knowledge garnered from studies on pluripotent stem cell provides a rich resource for can‐
cer stem cell research and paves the way in identifying novel key targets for cancer therapy.
Targeting molecules or pathways specific to embryonic stem cells gives us the opportunity
to kill cancer cells without harming innocent bystander cells.
The Dark Side of Pluripotency – Cancer Stem Cell
http://dx.doi.org/10.5772/54369
77
4. Summary
Research in cancer is immense and complex as cancer is a diverse disease with a myriad of
genetic mutations. A pressing practical concern in cancer therapeutics is the development of
resistance of cancer cells to current treatment, resulting in failure of therapy and eventual
death. In the last two decades, cancer stem cell hypothesis has emerged as the likely reason
for this resistance in cancer. We now understand that cancer stem cells are present in differ‐
ent cancers. They can be a small, distinct population characterized by certain phenotypes in
some cancers while heterogeneous and with no defining phenotypes in others. Cancer stem
cells can also result from cancer cells under the influence of environmental factors such as
hypoxia. They are also highly resistant to cancer drugs with several mechanisms employed
for enhanced survival. Research into stem cells and pluripotency regulatory networks will
provide further characterization and understanding of cancer stem cells. The information on
cancer stem cells has pieced together a therapeutic framework to address cancer resistance
with several potential therapies in clinical trials currently. So much more needs to be done
in this field in our quest to conquer cancer totally.
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